Skip to main content

Table 1 Clinical, imaging, and laboratory findings of the patients selected for the preparation of CSF seeds (CTR CSF: control patients’ group, AD CSF: Alzheimer’s disease group). Bold letters indicate pathological values of CSF tau, p-tau or Aβ. NIA-AA criteria: National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Criteria abbreviation: BP = “Biomarker probability of AD etiology” [2, 25]

From: Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice

patient number group diagnosis NIA-AA criteria alternative clinical diagnosis age MMS Brain MRI SPECT CSF tau (pg/ml) CSF p-tau (pg/ml) CSF Aβ (pg/ml)
1 CTR Dementia unlikely to be due to AD vascular encephalopathy 80 26 vascular encephalopathy no signs of AD or FTD, compatible with vascular encephalopathy 500 78 544
2 CTR Dementia unlikely to be due to AD neurocognitive deficits associated with progressive pancreas carcinoma and tumorectomy 73 25 mild vascular microangiopathy 206 50 580
3 CTR MCI - unlikely to be due to AD early Wernicke–Korsakoff syndrome 61 30 compatible with Wernicke-Korsakoff syndrome compatible with Wernicke-Korsakoff syndrome 162 43 928
4 CTR MCI - unlikely to be due to AD depression 57 28 normal 360 53 1133
1 AD Probable AD with high BP 73 25 hippocampal atrophy, no vascular lesions 840 105 366
2 AD Probable AD with high BP 61 24 temporal brain atrophy Left parietal decreased glucose metabolism compatible with early AD 500 92 318
3 AD MCI - core clinical data 79 28 mild hippocampal atrophy 759 119 516
4 AD Probable AD with intermediate BP 71 23 left hippocampal atrophy, microangiopathy 308 77 240
5 AD Probable AD with intermediate BP 74 21 hippocampal and global brain atrophy, mild microangiopathy 238 32 402